GVGiuseppa Di Vita

Giuseppa Di Vita

*This is an algorithmically generated author record based on publicly available information.

Giuseppa Di Vita has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    6p22.3 deletion: report of a patient with autism, severe intellectual disability and electroencephalographic anomalies

    by Daniela Di Benedetto, Giuseppa Di Vita, Corrado Romano, Mariangela Lo Giudice, Girolamo Aurelio Vitello, Marinella Zingale, Lucia Grillo, Lucia Castiglia, Sebastiano Antonino Musumeci, Marco Fichera

    The interstitial 6p deletions, involving the 6p22-p24 chromosomal region, are rare events characterized by variable phenotypes and no clear genotype-phenotype correlation has been established so far.


  • Use and tolerability of newer antipsychotics and antidepressants: a chart review in a paediatric setting

    by Marianna Alacqua, Gianluca Trifirò, Vincenzo Arcoraci, Eva Germanò, Angela Magazù, Tiziana Calarese, Giuseppa Di Vita, Catalda Gagliano, Edoardo Spina

    Objective To analyse the prescribing pattern and the safety profile of different atypical antipsychotics and selective serotonin reuptake inhibitors (SSRIs) during the years 2002–2003 in paediatric setting. Setting Two Child Neurology and Psychiatry Divisions of Southern Italy (University of Messina and “Oasi Institute for Research on Mental Retardation and Brain Aging” of Troina). Methods A retrospective chart review of all children and adolescents starting an incident treatment with atypical antipsychotics or SSRIs was performed. Within the first 3 months of therapy, any potential adverse drug reaction (ADR) was identified and the clinical outcome of psychotropic drug treatment was assessed. Main Outcome Measure Rate of ADR in the first 3 months of therapy with atypical antipsychotics and SSRIs in children and adolescents. Results On a total of 97 patients’ charts being reviewed, 73 (75%) concerned atypical antipsychotics and 24 (25%) SSRIs. Risperidone (N = 45, 62%) was the most frequently prescribed antipsychotic drug, followed by olanzapine (24, 32%). Overall, 50 (68%) antipsychotic users reported a total of 108 ADRs during the first 3 months of therapy, leading to drug discontinuation in 23 patients (31%). Among 24 users of SSRI, 12 (50%) received paroxetine, 6 (25%) sertraline, 5 (21%) citalopram and 1 (4%) fluoxetine. Only paroxetine users (21%) reported at least one ADR, however, none of SSRI users withdrew drug treatment within first 3 months. Conclusions ADRs occurred frequently during first 3 months of treatment with atypical antipsychotics and, to a lesser extent, with SSRIs in children and adolescents. Further investigations are urgently needed to better define the benefit/risk ratio of psychotropic medications in paediatric setting.


  • A New 6-bp SOX-3 Polyalanine Tract Deletion Does Not Segregate with Mental Retardation

    by Michele Salemi, Corrado Romano, Letizia Ragusa, Giuseppa Di Vita, Roberto Salluzzo, Ileana Oteri, Maria Luisa Trovato, Carmelo Romano, Filippo Caraci, Ferdinando Nicoletti, et al.

    SOX-3 is a transcription factor expressed throughout the developing central nervous system and is involved in maintenance of pluripotency in self-renewing stem cells, specification events, lineage progression, and terminal differentiation. An association between growth hormone deficiency, mental retardation, and Sox-3 mutations in humans was previously reported. The occurrence of abnormalities affecting the polyalanine tract of the Sox-3 gene was determined in a group of 77 unrelated mentally retarded patients without a definite genetic diagnosis and in 84 control subjects. A new SOX-3 polyalanine tract deletion was identified in a mentally impaired boy, in his mother (homozygous), and in 2 healthy brothers of the proband. This new mutation does not segregate with mental retardation.